Mithramycin Inhibits Myointimal Proliferation
After Mithramycin is a commercially available G-C-specific DNA binding drug that selectively inhibits transcription of genes, such as c-myc, that have G-C-rich promoter sequences. This study tested the hypothesis that mithramycin inhibits transcription of the c-myc proto-oncogene and prevents myointimal proliferation after balloon injury of the rat carotid artery in vivo.
Methods and Results Ten-week-old male Sprague-Dawley rats received mithramycin (150 gg/kg IP) or distilled H20 1 hour before and 1 hour after balloon injury of the right common carotid artery. After 2 weeks, the rats were killed by overdose of pentobarbital, and the injured right and uninjured control left arteries were pressure-fixed and subjected to morphological analysis for evaluation of the degree of myointimal thickening. Separate groups of rats were killed at 2 and 6 hours after vascular injury, and total RNA from injured and control vessels of mithramycin-and vehicle-treated rats was subjected to Northern analysis for assessment of steady-state c-myc mRNA levels. The areas of neointima and the ratios of neointimal to medial area were significantly less in mithramycin-treated than in control rats (0.6+0. Mithramycin is a G-C-specific DNA binding drug that selectively inhibits transcription of genes, such as the human c-myc gene, that have G-C-rich promoter sequences. [28] [29] [30] [31] [32] Mithramycin prevents the binding of Spl and other proteins to the c-myc P1 and P2 promoters.32 Previous studies have demonstrated that mithramycin prevents serum-induced proliferation of rat aortic smooth muscle cells and the concomitant increase in expression of c-myc proto-oncogene in vitro. 29 The current study tested the hypotheses that (1) mithramycin can prevent myointimal proliferation after balloon injury of rat carotid artery in vivo, (2) myointimal proliferation after vascular injury is associated with enhanced expression of the c-myc proto-oncogene, and (3) mithramycin inhibits the expression of c-myc mRNA in the damaged carotid artery. Our results suggest that c-myc participates in the proliferative response of the vascular wall to arterial injury and that overexpression of c-myc in the damaged artery can be effectively inhibited by mithramycin, and therefore that inhibition of c-myc with mithramycin may be therapeutically useful in preventing the proliferative lesion that occurs after coronary angioplasty.
Methods Animal Model
Ten-week-old male Sprague-Dawley rats weighing 300 to 350 g were obtained from Charles River Breeding Laboratories. Mithramycin (Sigma Chemical Co) in a dose of 150 ,ug/kg was dissolved in distilled H20 (120 ,g/mL) and administered by intraperitoneal injection 1 hour before and 1 hour after balloon injury of the right carotid artery. Control animals received injections of an equal volume of distilled H2O.
Animals were assigned at random to the mithramycin treatment or to distilled-H2O control groups. Rats were anesthetized with sodium pentobarbital (50 mg/kg IP), and the right carotid artery of each animal was isolated by a middle cervical incision, suspended on ties, and stripped of adventitia. The distal right common carotid artery and region of the bifurcation were exposed. A 2F Fogarty balloon catheter (Baxter V. Mueller, Irvine, Calif) was introduced through the external carotid artery and advanced into the thoracic aorta. 3 The balloon was inflated with saline to distend the common carotid artery and then was pulled back to the external carotid artery. After six repetitions of this procedure, the endothelium was removed completely, and some injury to medial smooth muscle layers throughout the common carotid artery resulted. After removal of the catheter, the external carotid artery was ligated and the wound closed. The left carotid artery was not damaged and served as the control.
Animals were given standard rat chow and tap water ad libitum for 2 weeks, at which time they were killed with an overdose of sodium pentobarbital (75 mg/kg) and perfused with 10% formalin at a pressure of 120 mm Hg. The vascular system was rinsed with 10 mL PBS before infusion of fixative solution. Both carotid arteries were isolated from adherent tissue and fixed in 10% formalin for morphometric analysis. 
Morphometric Analysis
For histological analysis, vessels were embedded in paraffin and the middle fifth (0.2 cm) of the damaged right carotid artery was serially sectioned (30 gm). The left carotid artery was not damaged and served as a control. Morphometric analysis of each arterial segment was performed with a computer-based Bioquant II morphometric system. Tissue was stained with Verhoeffs elastic tissue staining, which demonstrated several layers of elastic laminae (Fig 1) . At least five sections of each vessel were examined, and the measurements were averaged for statistical analysis. All morphometric analyses were carried out by a single examiner, who was blinded with respect to the experimental group to which each sample belonged. The cross-sectional surface areas of the vessel with the external elastic lamella (the total area), within the internal elastic lamina (the intimal area), and within the lumen (the lumen area) were measured. The degree of myointimal proliferation of the injured carotid artery was expressed as the absolute area of neointima and the ratio of the neointimal area to the medial area.
RNA Isolation and Northern Blot Analysis
In a separate experiment, 10-week-old male Sprague-Dawley rats received mithramycin (150 ,ug/kg IP) or distilled H20 1 hour before and 1 hour after balloon catheterization. At 2 and 6 hours after vascular injury, rats were killed by an overdose of sodium pentobarbital (75 mg/kg). Fresh (model Imaging Densitometer, Bio-Rad). To estimate vessel steady-state c-myc mRNA levels, the c-myc mRNA to 18S rRNA ratios were determined by dividing the absorbance corresponding to mouse c-myc cDNA probe hybridization by the absorbance corresponding 18S rRNA probe hybridization.
Statistical Analysis
Results were expressed as mean±SEM. Data were analyzed with the CRUNCH statistical package on an IBM PC/AT computer. Statistical comparisons of neointimal area, medial area, total area, lumen area, ratio of neointimal area to medial area, and ratio of c-myc mRNA to 18S rRNA between mithramycin-treated and control groups were performed with Student's unpaired t test. Differences were reported as significant at a value of P<.05.
Results
Two weeks after balloon injury of rat carotid artery, the body weight of mithramycin-treated rats was not different from that of control rats (389+9 g, n=6 versus 378+22 g, n=7, respectively), indicating that 150 gg/kg of mithramycin administered 1 hour before and 1 hour after carotid arterial injury was not toxic to the rats. In the undamaged left carotid artery of both mithramycintreated and control groups, the intima was only a single cell layer thick; the internal elastic lamina was intact, and the external elastic lamina was in contact with the adventitia (Fig 1, top) . Two weeks after balloon injury of the right carotid artery, significant proliferation of the neointima consisting of circumferentially uniform, multiple layers of smooth muscle cells was observed in the damaged vessel (Fig 1, middle) . Furthermore, the internal elastic lamina was disrupted. The extensive neointimal proliferation was associated with a reduced residual lumen area (Fig 1, middle) . In mithramycintreated rats, the degree of neointimal proliferation of the damaged carotid artery was much less extensive than in vehicle-treated control rats (Fig 1, bottom) .
Morphometric analysis showed significant suppression (:50%) of myointimal formation in mithramycintreated compared with vehicle-treated control rats (0.6±0.1 versus 1.2-+ 0.1 mm2, respectively, P<.01) (Fig   2, top) . The ratios of neointimal area to medial area were markedly less in mithramycin-treated rats than in vehicle-treated control rats (95±16% versus 190±14%, respectively, P<.01) (Fig 2, middle) . The lumen sizes were significantly decreased in the vehicle-treated control rats compared with the mithramycin-treated rats (0.8±0.1 versus 1.5+0.1 mm2' P<.01) (Fig 2, bottom) .
Compared with vehicle-treated control rats, there was no significant change in the total area (2.70±0. 17 Northern analysis showed that expression of c-myc mRNA in undamaged carotid artery was low and barely detectable but that steady-state c-myc mRNA levels increased significantly following vascular injury. The c-myc signal was maximal at 2 hours and persisted 6 hours following balloon injury. Compared with the undamaged carotid artery, the magnitude of the increase of c-myc mRNA, measured by densitometric scanning, was 10-fold and 6-fold at 2 and 6 hours after balloon injury, respectively. Mithramycin significantly inhibited expression of c-myc gene transcription levels by 66% and 53% at 2 and 6 hours after balloon injury, respectively, compared with damaged control vessels from vehicle-treated rats (Fig 3) . 
Discussion
This study demonstrated that (1) mithramycin, a G-C-specific DNA binding drug, significantly inhibits myointimal proliferation following balloon injury of the rat carotid artery in vivo, (2) expression of the c-myc proto-oncogene is increased acutely (10-fold increase at 2 hours) following balloon injury, and (3) mithramycin significantly inhibits c-myc expression in damaged vessels when administered systemically immediately before and after injury of the carotid artery in doses that are not toxic to rats.
An immediate early-response gene, c-myc is expressed in nearly all cell types and appears to play an important role in regulating cellular proliferation and differentiation. (1) undamaged left common carotid artery (z), (2) phase) and remain increased throughout the cell cycle in the presence of growth factors. Studies using other cell systems have shown that downregulation of c-myc expression is invariably associated with the inhibition of cell growth and induction of differentiation. 26 Antisense inhibition of c-myc expression in cultured vascular smooth muscle cells is associated with inhibition of cell proliferation and migration, as well as decreased expression of c-myc protein as detected by Western immunoblotting and immunocytochemical staining. Serum-stimulated induction of c-myc expression is blunted by treatment with antisense oligonucleotides. 38 Shi and coworkers27 reported that antisense oligomers directed toward the translation initiation region of the human c-myc gene have a significant antiproliferative effect on human vascular smooth muscle cells in culture, whereas the sense and mismatched oligomers do not have a growth-inhibitory effect. Simons and Rosenberg16 showed that the c-myb protooncogene, which is homologous to the transforming gene product of the avian myeloblastosis virus, is overexpressed in proliferating vascular smooth muscle cells in vitro. Simons et all8 showed that suppression of the increase in c-myb mRNA by local application of antisense oligonucleotide inhibits smooth muscle proliferation both in vitro and in a carotid artery injury model in vivo. Thus, inhibition of both c-myc and c-myb prevents proliferation of smooth muscle cells, confirming their essential roles in vascular smooth muscle cell growth stimulation. This study has demonstrated that c-myc expression is increased acutely as much as 10- transcription by G-C-specific DNA binding drugs may allow the development of more specific "antigene therapies," such as triplex-forming transcriptional inhibitors. 44 Furthermore, because mithramycin is known to be an effective inhibitor of human c-myc gene transcription in vivo in doses that are safe and well tolerated, it offers promise for the prevention of coronary artery restenosis in human subjects.
